文献速递认知障碍与痴呆脑血管病

携带APOEε2等位基因的阿尔茨海默病患者的临床表型、萎缩与脑小血管病

Clinical phenotype, atrophy, and small vessel disease in APOEε2 carriers with Alzheimer disease.
PubMed 文献 · Neurology · 2018-10-19

研究纳入36例β-淀粉样蛋白阳性的APOEε2携带者(均为ε2/ε3)合并轻度认知障碍或阿尔茨海默病痴呆,按年龄和诊断1:2匹配APOEε3纯合子和APOEε4携带者。结果显示ε2携带者非记忆域表现更差、记忆相对ε4携带者更好,伴不对称左侧为主颞顶叶萎缩、白质高信号体积大于ε4携带者(平均10.4 vs 7.3 mL)及微出血患病率高于ε3纯合子(37.5% vs 18.3%)。

要点

  • ε2携带者非记忆域认知表现较ε3纯合子和ε4携带者更差,记忆表现优于ε4携带者。
  • ε2携带者较ε4携带者呈现不对称左侧为主颞顶叶萎缩,内侧颞叶受累略轻。
  • ε2携带者白质高信号体积大于ε4携带者,微出血患病率高于ε3纯合子。

核心结论

  • 携带保护性APOEε2等位基因仍发展为阿尔茨海默病的患者表现为非遗忘型临床表型,并伴更严重的脑小血管病。

研究设计与样本

  • 研究纳入36例经脑脊液或PET证实β-淀粉样蛋白阳性的APOEε2携带者(均为ε2/ε3),合并轻度认知障碍或阿尔茨海默病痴呆,按年龄和诊断以1:2比例匹配APOEε3纯合子和APOEε4携带者(70%为ε3/ε4,30%为ε4/ε4)。
  • 评估4个认知域(记忆、注意力、执行、语言)的神经心理表现,对T1加权MRI行基于体素和感兴趣区的灰质萎缩分析,用液体衰减反转恢复图像自动定量白质高信号体积,用T2*加权图像识别微出血。
  • 采用方差分析比较ε2携带者、ε3纯合子和ε4携带者间认知域评分、萎缩和白质高信号的差异,用Pearson χ2检验比较微出血患病率差异。

主要发现

  • ε2携带者在非记忆域表现较ε3纯合子和ε4携带者更差,但在记忆域表现优于ε4携带者。
  • 基于体素的T1加权MRI分析显示,与ε4携带者相比,ε2携带者呈现不对称(左侧大于右侧)颞顶叶为主的萎缩,内侧颞叶结构受累略轻。
  • ε2携带者白质高信号总体积大于ε4携带者(平均10.4 vs 7.3 mL)。
  • ε2携带者微出血患病率高于ε3纯合子(37.5% vs 18.3%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the clinical phenotype, gray matter atrophy patterns, and small vessel disease in patients who developed prodromal or probable Alzheimer disease dementia, despite carrying the protective APOEε2 allele. METHODS: We included 36 β-amyloid-positive (by CSF or PET) APOEε2 carriers (all ε2/ε3) with mild cognitive impairment or dementia due to Alzheimer disease who were matched for age and diagnosis (ratio 1:2) to APOEε3 homozygotes and APOEε4 carriers (70% ε3/ε4 and 30% ε4/ε4). We assessed neuropsychological performance across 4 cognitive domains (memory, attention, executive, and language functions), performed voxelwise and region of interest analyses of gray matter atrophy on T1-weighted MRI, used fluid-attenuated inversion recovery images to automatically quantify white matter hyperintensity volumes, and assessed T2*-weighted images to identify microbleeds. Differences in cognitive domain scores, atrophy, and white matter hyperintensities between ε2 carriers, ε3 homozygotes, and ε4 carriers were assessed using analysis of variance analyses, and Pearson χ2 tests were used to examine differences in prevalence of microbleeds. RESULTS: We found that ε2 carriers performed worse on nonmemory domains compared to both ε3 homozygotes and ε4 carriers but better on memory compared to ε4 carriers. Voxelwise T1-weighted MRI analyses showed asymmetric (left > right) temporoparietal-predominant atrophy with subtly less involvement of medial-temporal structures in ε2 carriers compared to ε4 carriers. Finally, ε2 carriers had larger total white matter hyperintensity volumes compared to ε4 carriers (mean 10.4 vs 7.3 mL) and a higher prevalence of microbleeds compared to ε3 homozygotes (37.5% vs 18.3%). CONCLUSION: APOEε2 carriers who develop Alzheimer disease despite carrying the protective allele display a nonamnestic clinical phenotype with more severe small vessel disease.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Groot C, Sudre CH, Barkhof F, et al. Clinical phenotype, atrophy, and small vessel disease in APOEε2 carriers with Alzheimer disease. Neurology. 2018. PMID: 30341156. doi:10.1212/WNL.0000000000006503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。